远大医药全球创新型内源性组织修复产品aXess取得关键性临床试验的成功数据

远大医药官微
Oct 09

远大医药(0512.HK)全球创新型内源性组织修复产品aXess近日取得了关键性临床试验(aXess EU)的成功数据,该试验证明aXess在血液透析治疗领域具有革命性潜力。关于aXess EUaXess EU是一项前瞻性研究,旨在评估aXess在需要建立血管通路以开始或维持血液透析的终末期肾病患者中的通畅性、安全性和性能。本项研究在欧洲18个中心开展。具体研究结果:与标准疗法相比,aXess在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10